3wbl
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | + | ==Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitor== | |
- | + | <StructureSection load='3wbl' size='340' side='right' caption='[[3wbl]], [[Resolution|resolution]] 2.00Å' scene=''> | |
- | + | == Structural highlights == | |
+ | <table><tr><td colspan='2'>[[3wbl]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3WBL OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3WBL FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=PDY:N~7~-(4-ETHOXYPHENYL)-6-METHYL-N~5~-[(3S)-PIPERIDIN-3-YL]PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE'>PDY</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3a2c|3a2c]]</td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CDK2, CDKN2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> | ||
+ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Cyclin-dependent_kinase Cyclin-dependent kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.22 2.7.11.22] </span></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3wbl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3wbl OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3wbl RCSB], [http://www.ebi.ac.uk/pdbsum/3wbl PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Mitogen-activated protein kinase-activated protein kinase 2 (MK2 or MAPKAP-K2) is a Ser/Thr kinase from the p38 mitogen-activated protein kinase signalling pathway and plays an important role in inflammatory diseases. The crystal structure of the MK2-TEI-I01800 complex has been reported; its Gly-rich loop was found to form an alpha-helix, not a beta-sheet as has been observed for other Ser/Thr kinases. TEI-I01800 is 177-fold selective against MK2 compared with CDK2; in order to understand the inhibitory mechanism of TEI-I01800, the cyclin-dependent kinase 2 (CDK2) complex structure with TEI-I01800 was determined at 2.0 A resolution. Interestingly, the Gly-rich loop of CDK2 formed a beta-sheet that was different from that of MK2. In MK2, TEI-I01800 changed the secondary structure of the Gly-rich loop from a beta-sheet to an alpha-helix by collision between Leu70 and a p-ethoxyphenyl group at the 7-position and bound to MK2. However, for CDK2, TEI-I01800 bound to CDK2 without this structural change and lost the interaction with the substituent at the 7-position. In summary, the results of this study suggest that the reason for the selectivity of TEI-I01800 is the favourable conformation of TEI-I01800 itself, making it suitable for binding to the alpha-form MK2. | ||
- | + | Crystal structure of human cyclin-dependent kinase-2 complex with MK2 inhibitor TEI-I01800: insight into the selectivity.,Fujino A, Fukushima K, Kubota T, Kosugi T, Takimoto-Kamimura M J Synchrotron Radiat. 2013 Nov;20(Pt 6):905-9. doi: 10.1107/S0909049513020736., Epub 2013 Sep 26. PMID:24121337<ref>PMID:24121337</ref> | |
- | + | ||
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | == | + | ==See Also== |
- | + | *[[Cell division protein kinase 2|Cell division protein kinase 2]] | |
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
[[Category: Cyclin-dependent kinase]] | [[Category: Cyclin-dependent kinase]] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
- | [[Category: Fujino, A | + | [[Category: Fujino, A]] |
- | [[Category: Fukushima, K | + | [[Category: Fukushima, K]] |
- | [[Category: Kosugi, T | + | [[Category: Kosugi, T]] |
- | [[Category: Kubota, T | + | [[Category: Kubota, T]] |
- | [[Category: Takimoto-Kamimura, M | + | [[Category: Takimoto-Kamimura, M]] |
[[Category: Binding site]] | [[Category: Binding site]] | ||
[[Category: Cyclin-dependent kinase 2]] | [[Category: Cyclin-dependent kinase 2]] |
Revision as of 09:58, 21 December 2014
Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitor
|
Categories: Cyclin-dependent kinase | Homo sapiens | Fujino, A | Fukushima, K | Kosugi, T | Kubota, T | Takimoto-Kamimura, M | Binding site | Cyclin-dependent kinase 2 | Drug design | Map kinase kinase 2 | Mk2 | Protein kinase inhibitor | Pyrazole | Pyrimidine | Structure-activity relationship | Transferase-transferase inhibitor complex | Tumor